

Roy B Tishler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2400464/publications.pdf>

Version: 2024-02-01

62
papers

3,002
citations

218381

26
h-index

168136

53
g-index

65
all docs

65
docs citations

65
times ranked

3803
citing authors

#	ARTICLE	IF	CITATIONS
1	Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. <i>Lancet Oncology</i> , 2013, 14, 257-264.	5.1	617
2	Taxol: A novel radiation sensitizer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1992, 22, 613-617.	0.4	293
3	Dose to Larynx Predicts for Swallowing Complications After Intensity-Modulated Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1110-1118.	0.4	211
4	Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 1563.	3.4	198
5	Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. <i>Cancer</i> , 2016, 122, 3632-3640.	2.0	145
6	Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1660-1667.	1.1	127
7	Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2003, 97, 412-418.	2.0	90
8	Clinical Practice Guidance for Radiotherapy Planning After Induction Chemotherapy in Locoregionally Advanced Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 725-733.	0.4	80
9	Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2017, 7, 246-253.	1.1	73
10	Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: Evolution of the sequential treatment approach. <i>Seminars in Oncology</i> , 2004, 31, 778-785.	0.8	66
11	Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. <i>British Journal of Cancer</i> , 2016, 115, 252-260.	2.9	66
12	A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 134-144.	0.4	61
13	Merkel Cell Carcinoma: A Population Analysis on Survival. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1247-1257.	2.3	57
14	The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. <i>Oncologist</i> , 2017, 22, 343-350.	1.9	57
15	A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2002, 95, 1472-1481.	2.0	55
16	Changing prognostic significance of tumor stage and nodal stage in patients with squamous cell carcinoma of the oropharynx in the human papillomavirus era. <i>Cancer</i> , 2015, 121, 2594-2602.	2.0	53
17	Endoscopic Management of Hypopharyngeal Stenosis after Organ Sparing Therapy for Head and Neck Cancer. <i>Laryngoscope</i> , 2004, 114, 1924-1931.	1.1	51
18	Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 2939-2949.	3.2	51

#	ARTICLE	IF	CITATIONS
19	Efficacy and Toxicity of Chemoradiotherapy Using Intensity-Modulated Radiotherapy for Unknown Primary of Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1405-1411.	0.4	50
20	Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2022, 28, 468-478.	3.2	45
21	Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 191.	1.3	42
22	An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 43, 1001-1008.	0.4	35
23	Cost-Effectiveness Analysis of Chemoradiation Therapy Versus Transoral Robotic Surgery for Human Papillomavirus-Associated, Clinical N2 Oropharyngeal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 512-522.	0.4	35
24	A phase II study of nivolumab (N) plus ipilimumab (I) in radiiodine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 6513-6513.	0.8	34
25	Cost-Effectiveness Analysis of Intensity Modulated Radiation Therapy Versus Proton Therapy for Oropharyngeal Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 875-882.	0.4	28
26	Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1036-1044.	0.4	26
27	The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers. <i>Oncologist</i> , 2020, 25, 598-608.	1.9	26
28	Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 137-145.	0.4	24
29	Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. <i>Cancer Biomarkers</i> , 2017, 19, 129-136.	0.8	22
30	Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma. <i>Oral Oncology</i> , 2020, 106, 104690.	0.8	21
31	Patterns of failure after reirradiation with intensity-modulated radiation therapy and the competing risk of out-of-field recurrences. <i>Oral Oncology</i> , 2016, 61, 19-26.	0.8	20
32	Short-term mortality risks among patients with oropharynx cancer by human papillomavirus status. <i>Cancer</i> , 2020, 126, 1424-1433.	2.0	20
33	Thyroid Malignancies in Survivors of Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 636-641.	0.4	19
34	Acupuncture for Chemoradiation Therapy-Related Dysphagia in Head and Neck Cancer: A Pilot Randomized Sham-Controlled Trial. <i>Oncologist</i> , 2016, 21, 1522-1529.	1.9	18
35	Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients. , 2016, 4, 32.		17
36	Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2020, 105, 104676.	0.8	16

#	ARTICLE	IF	CITATIONS
37	Adjuvant radiation following clear margin resection of high T-stage cutaneous squamous cell carcinoma halves the risk of local and locoregional recurrence: A dual-center retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 87-94.	0.6	14
38	Exposed bone in patients with head and neck cancer treated with radiation therapy: An analysis of the Observational Study of Dental Outcomes in Head and Neck Cancer Patients (OraRad). <i>Cancer</i> , 2022, 128, 487-496.	2.0	12
39	Population-based validation of the recursive partitioning analysis-based staging system for oropharyngeal cancer. <i>Head and Neck</i> , 2016, 38, 1530-1538.	0.9	9
40	A comparative study of standard intensity-modulated radiotherapy and RapidArc planning techniques for ipsilateral and bilateral head and neck irradiation. <i>Medical Dosimetry</i> , 2017, 42, 31-36.	0.4	9
41	Prospective analysis of radiation oncology image and plan-driven peer review for head and neck cancer. <i>Head and Neck</i> , 2017, 39, 1603-1608.	0.9	9
42	Funding Support and Principal Investigator Leadership of Oncology Clinical Trials Using Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 34-43.	0.4	9
43	Ensuring Head and Neck Oncology Patients Receive Recommended Pretreatment Dental Evaluations. <i>Journal of Oncology Practice</i> , 2015, 11, 151-154.	2.5	8
44	A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 132-139.	0.4	8
45	IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing. <i>Head and Neck</i> , 2019, 41, 959-966.	0.9	8
46	Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19. <i>Oral Oncology</i> , 2021, 112, 105087.	0.8	8
47	Radiation Oncology—New Approaches in Squamous Cell Cancer of the Head and Neck. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 1093-1106.	0.9	7
48	Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience. <i>Head and Neck</i> , 2016, 38, E1618-24.	0.9	7
49	Microcystic Adnexal Carcinoma of the Face Treated With Definitive Chemoradiation: A Case Report and Review of the Literature. <i>Advances in Radiation Oncology</i> , 2020, 5, 301-310.	0.6	7
50	Neoadjuvant and adjuvant nivolumab and liriumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck. <i>Journal of Clinical Oncology</i> , 2021, 39, 6053-6053.	0.8	7
51	Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes. <i>Head and Neck</i> , 2022, 44, 722-734.	0.9	6
52	Outcomes following radiation for cutaneous squamous cell carcinoma of the head and neck: Associations between immune suppression and recurrence. <i>Head and Neck</i> , 2019, 41, 2111-2115.	0.9	4
53	Synchronous squamous cell carcinoma and diffuse large B-cell lymphoma of the head and neck: the odd couple. <i>BJR case Reports</i> , 2016, 2, 20150271.	0.1	3
54	Medical Malpractice Analysis in Radiation Oncology: A Decade of Results From a National Comparative Benchmarking System. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 801-808.	0.4	3

#	ARTICLE	IF	CITATIONS
55	Patient reported outcomes in patients with head and neck cancer treated with concurrent chemoradiation with weekly versus bolus cisplatin. <i>Head and Neck</i> , 2020, 42, 3670-3677.	0.9	3
56	Association between treatment center experience and survival after diagnosis of stage I to III Merkel cell carcinoma treated with surgery with or without postoperative radiation therapy. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 875-877.	0.6	3
57	Association between radiation dose to organs at risk and acute patient reported outcome during radiation treatment for head and neck cancers. <i>Head and Neck</i> , 2022, , .	0.9	3
58	Increased clarity on the use of radiotherapy in the management of desmoplastic melanoma. <i>Cancer</i> , 2014, 120, 1315-1318.	2.0	2
59	Head and Neck Cancer Clinical Research on ClinicalTrials.gov: An Opportunity for Radiation Oncologists. <i>Advances in Radiation Oncology</i> , 2021, 6, 100608.	0.6	2
60	Analysis of immune infiltrates in a genomically characterized clinical cohort of head and neck squamous cell carcinoma (HNSCC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6052-6052.	0.8	1
61	The Prognostic Value of Thymidylate Synthase and p53 Expression in Patients Treated with Induction Chemotherapy for Squamous Cell Carcinoma of the Head and Neck. <i>Oncologist</i> , 1998, 3, 424-431.	1.9	1
62	Retrospective review of patients treated with intensity modulated radiation therapy (IMRT) with or without concurrent chemotherapy for locally advanced thyroid cancer: The Dana-Farber experience.. <i>Journal of Clinical Oncology</i> , 2012, 30, e16060-e16060.	0.8	0